Related Experiment Videos
Variable response to inhaled nitric oxide after cardiac surgery
D A Fullerton1, J Jaggers, M M Wollmering
1Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA. dfullert@nmh.org
The Annals of Thoracic Surgery
|May 1, 1997
Summary
Inhaled nitric oxide (NO) effectively reduced pulmonary hypertension in cardiac surgery patients without valvular heart disease. However, patients with valvular heart disease showed no response, indicating a need for alternative therapies.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Pulmonary hypertension is a significant concern in cardiac surgical patients, often linked to pulmonary vascular remodeling in valvular heart disease.
- Inhaled nitric oxide (NO) presents a potential therapeutic strategy for managing pulmonary hypertension post-cardiac surgery.
Purpose of the Study:
- To evaluate and compare the effectiveness of inhaled NO in cardiac surgical patients experiencing pulmonary hypertension, differentiating between those with and without valvular heart disease.
Main Methods:
- A study involving 40 parts per million (ppm) of inhaled NO was conducted in the operating room on cardiac surgical patients with pulmonary hypertension (mean pulmonary artery pressure ≥ 30 mm Hg).
- The study included 15 patients with valvular heart disease as the study group and 25 patients undergoing aortocoronary bypass grafting as controls.
Main Results:
- In patients undergoing aortocoronary bypass grafting, inhaled NO significantly decreased mean pulmonary artery pressure by 24% and pulmonary vascular resistance by 36% without affecting systemic blood pressure.
- Conversely, patients with pulmonary hypertension due to valvular heart disease demonstrated no significant response to inhaled NO, with persistent high mean pulmonary artery pressure and pulmonary vascular resistance.
Conclusions:
- The efficacy of inhaled NO in managing pulmonary hypertension among cardiac surgical patients is variable.
- These findings suggest that while inhaled NO shows promise as a pulmonary vasodilator, alternative treatments are necessary for patients with pulmonary hypertension stemming from valvular heart disease.